EP2505204
Aðferð til meðhöndlunar á krabbameini í blöðruhálskirtli með GnRH-mótlyfinu degarelix
Status:
EP Einkaleyfi fallið úr gildiEP appl. date:
10.2.2009EP published:
24.12.2014EP application number:
12165896.7
EP translation filed:
18.2.2015Grant published:
15.3.2015EPO information:
European Patent Register
Max expiry date:
9.2.2029Expiry date:
9.2.2019
Title:
Method of treating prostate cancer with the GnRH antagonist degarelix
Timeline
Today
10.2.2009EP application
24.12.2014EP Publication
18.2.2015Translation submitted
15.3.2015Registration published
9.2.2019Expires
Owner
Name:
Ferring B.V.Address:
Polaris Avenue 144, 2132, JX Hoofddorp, NL
Inventor
Name:
Olesen, Tine KoldAddress:
New York, NY, US
Name:
Persson, Bo-EricAddress:
Rolle, CH
Name:
Cantor, PerAddress:
Charlottenlund, DK
Name:
van der Meulen, Egbert AAddress:
Dalby, SE
Name:
Jensen, Jens-Christian, SlottAddress:
Bagsvaerd, DK
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
27741 PDate:
11.2.2008Country:
US
Number:
08250703Date:
29.2.2008Country:
EP
Classification
Categories:
A61K 38/08, A61K 38/09, A61P 35/00
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 7.5.2015
Expires: 9.2.2016
Payer: Árnason Faktor
Number: 8
Paid: 5.1.2016
Expires: 9.2.2017
Payer: Árnason Faktor
Number: 9
Paid: 9.1.2017
Expires: 9.2.2018
Payer: Árnason Faktor
Number: 10
Paid: 26.2.2018
Expires: 9.2.2019
Payer: Tego ehf.